AUTHORS
Daniela Carolina Carolina Bravo Solarte, MD, Ghada Araji, MD2, Melanie Jugl3, Jongphil Kim, PhD4, Kriti Gera, MD5, Hana Qasim, Fellow6, Taiga Nishihori, MD7, Alaa Ali, MD8, Rawan Faramand, MD9, Farhad Khimani, MD10, Sayeef Mirza, BS, MPH, MD11, Hien Liu, MD12, Brahm Segal, MD13, Sameh Gaballa, MD14, Michael D. Jain, MD, PhD15, Frederick L. Locke, MD16, Bijal Shah, MD, MS17, Nima Ghalehsari, MD18, Aleksandr Lazaryan, MD MPH PhD19
AFFILIATIONS
1 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
2 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
3 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
4 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
5 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
6 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
7 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
8 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
9 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
10 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
11 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
12 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
13 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
14 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
15 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
16 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
17 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
18 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
19 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
ABSTRACT
Brexucabtagene autoleucel (brexu-cel) is a standard-of-care CD19-directed CAR T-cell therapy for relapsed/refractory mantle cell lymphoma (MCL). ZUMA-2 5-year follow-up showed ~1/3 of patients in remission beyond 4 years, yet severe toxicities and heterogeneous durability of response remain clinically important challenges. Toxicity- and progression-free survival at 6 months (TPFS6) is a composite endpoint designed to capture net CAR T benefit (Saha, Lazaryan et al., BMT 2026). We evaluated an MCL-specific TPFS6 construct and its prognostic significance following brexu-cel therapy.
MCL-TPFS6 was defined as absence of failure to achieve complete response (CR) at 6 months, grade ≥3 cytokine release syndrome (CRS), grade ≥3 immune effector cell-associated neurotoxicity syndrome (ICANS), non-relapse mortality (NRM), or prolonged (≥60 days) grade 4 neutropenia and/or thrombocytopenia requiring growth factor and/or transfusion support within 6 months of brexu-cel. We analyzed 75 consecutive MCL patients treated with brexu-cel at a single center. Multivariable logistic regression identified predictors of MCL-TPFS6 failure. 6-month landmark analyses evaluated associations between MCL-TPFS6 and subsequent overall survival (OS) and progression-free survival (PFS). Additional multivariable landmark analyses assessed whether MCL-TPFS6 retained prognostic significance independent of early progressive disease/stable disease (PD/SD).
Median age was 71 years (range, 41-80), 76% were male, 64% had prior Bruton tyrosine kinase inhibitor (BTKi) exposure, 27% harbored TP53 mutation, 27% had blastoid histology, and 75% had received ≥2 prior lines of therapy. Among 75 patients treated with brexu-cel, 30 (40%) achieved MCL-TPFS6. Only one patient in partial response at 6 months subsequently converted to CR, supporting use of CR as the efficacy component of MCL-TPFS6. Among MCL-TPFS6 failures (n=45), grade ≥3 ICANS was the most frequent component (44.4%), followed by PD/SD (35.6%), grade ≥3 CRS (11.1%), prolonged grade 4 neutropenia/thrombocytopenia (6.7%), and NRM (2.2%). Overall, toxicity-related events accounted for 64.4% of MCL-TPFS6 failures. Patients with MCL-TPFS6 failure were more likely to have baseline C-reactive protein (CRP) ≥4 mg/dL (36% vs 10%, p=0.015), lactate dehydrogenase (LDH) >1× upper limit of normal (ULN) (56% vs 27%, p=0.018), and prior BTKi exposure (80% vs 40%, p<0.001). MCL-TPFS6 was not associated with age, sex, race/ethnicity, ferritin, histology, TP53 mutation, or receipt of ≥2 prior lines of therapy (all p>0.05). On multivariable logistic regression, prior BTKi exposure (OR 6.11, 95% CI 2.14-19.1; p=0.001) and LDH >1× ULN (OR 3.53, 95% CI 1.22-11.2; p=0.024) independently predicted MCL-TPFS6 failure. In the 6-month OS landmark analysis, MCL-TPFS6 failure independently predicted inferior OS (HR 4.56, 95% CI 1.29-16.0; p=0.018), as did CRP ≥4 mg/dL (HR 2.92, p=0.019) and LDH >1× ULN (HR 3.85, p=0.007). To evaluate whether MCL-TPFS6 provided prognostic information beyond early disease resistance, MCL-TPFS6 failures were separated into PD/SD- and toxicity-related failures. On multivariable landmark analysis, both PD/SD-related (HR 11.0, 95% CI 2.49-49.1; p=0.002) and toxicity-related failures (HR 4.82, 95% CI 1.13-20.6; p=0.034) were independently associated with inferior OS. Corresponding 5-year OS estimates were 83%, 44%, and 10% for MCL-TPFS6 achievers, toxicity-related failures, and PD/SD-related failures, respectively. In contrast, MCL-TPFS6 was not independently associated with subsequent PFS in landmark analysis, whereas LDH >1× ULN remained predictive of inferior PFS (HR 2.84, 95% CI 1.07-7.54; p=0.036).
MCL-TPFS6 is a robust composite endpoint that captures both treatment efficacy and clinically consequential toxicity following brexu-cel. Prior BTKi exposure and elevated LDH identify patients at greatest risk for MCL-TPFS6 failure. While early PD/SD events with MCL-TPFS6 remained strongly associated with mortality, toxicity-related MCL-TPFS6 failures independently predicted inferior OS, demonstrating that severe CAR T-related toxicities provide prognostic information beyond early disease resistance. Pending validation in larger multicenter cohorts, MCL-TPFS6 may serve as an early measure of net treatment benefit and a candidate surrogate endpoint for future CAR T studies, integrating both disease control and severe toxicity into a single clinically meaningful outcome.
DISCLOSURES
Daniela Carolina Carolina Bravo Solarte, MD: No relevant conflicts of interest to declare.